Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Hindu
The Hindu
National
Bindu Shajan Perappadan

ICMR got ₹171.74 crore in royalty from Covaxin sale, Rajya Sabha told

A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial after it was approved by the Indian Council of Medical Research (ICMR), at Maharaja Agrasen Super Speciality Hospital in Jaipur. File Photo. (Source: PTI)

Indian Council of Medical Research (ICMR) has received royalty of ₹171.74 crore till 31st January, 2022 from Bharat Biotech from sales of COVID vaccine Covaxin. The Council has spent around ₹35 crore in research and development of Covaxin.

Funds with ICMR are utilised for health research activities, including emerging research priorities and research capacity building, the Health Ministry told the Upper House of Parliament on Tuesday in response to a question by Leader of Opposition in the Rajya Sabha Mallikarjun Kharge.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.